A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.

The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.

0.6 ml, placebo injection, biweekly subcutaneous abdominal injections for 26 weeks (core treatment period), after which placebo was randomized 1:1 to JY09 (1.2 mg) and JY09 (2.4 mg) continued subcutaneous abdominal injections biweekly for 28 weeks (extended treatment period).